You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 4,951,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,951,675
Title: Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
Abstract:This invention relates to materials exhibiting certain magnetic and biological properties which make them uniquely suitable for use as magnetic resonance imaging (MRI) agents to enhance MR images of animal organs and tissues. More particularly, the invention relates to the in vivo use of biologically degradable and metabolizable superparamagnetic metal oxides as MR contrast agents. Depending on their preparation, these metal oxides are in the form of superparamagnetic particle dispersoids or superparamagnetic fluids where the suspending medium is a physiologically-acceptable carrier, and may be uncoated or surrounded by a polymeric coating to which biological molecules can be attached. These materials are administered to animals, including humans, by a variety of routes and the metal oxides therein collect in specific target organs to be imaged; in the case of coated particles, the biological molecules can be chosen to target specific organs or tissues. The biodistribution of the metal oxides in target organs or tissues results in a more detailed image of such organs or tissues because the metal oxides, due to their superparamagnetic properties, exert profound effects on the hydrogen nuclei responsible for the MR image. In addition, the dispersoids and fluids are quite stable and, in the case of the fluids, can even be subjected to autoclaving without impairing their utility. Furthermore, the materials are biodegradable and, in the case of iron oxide compounds, can eventually be incorporated into the subject's hemoglobin, making them useful in treating anemia. Thus, the materials are well-suited for in vivo use.
Inventor(s): Groman; Ernest V. (Brookline, MA), Josephson; Lee (Arlington, MA), Lewis; Jerome M. (Newton, MA)
Assignee: Advanced Magnetics, Incorporated (Cambridge, MA)
Application Number:07/244,432
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 4,951,675: A Comprehensive Analysis

Introduction

United States Patent 4,951,675, though not directly mentioned in the provided sources, can be analyzed within the context of patent law, procedures, and the broader patent landscape. This article will delve into the general principles of patent claims, the process of correcting inventorship, and the administrative and judicial mechanisms that shape the patent landscape in the United States.

Patent Claims and Scope

What are Patent Claims?

Patent claims define the scope of protection granted by a patent. They are the legal boundaries that distinguish the invention from prior art and other inventions. The clarity and specificity of claims are crucial for determining the validity and enforceability of a patent[3].

Analyzing Patent Claims

When analyzing a patent like 4,951,675, it is essential to parse the claims to understand the invention's scope. This involves identifying the independent and dependent claims, as well as the relationships between them. The Patent Claims Research Dataset provided by the USPTO can be a valuable resource for this analysis, offering detailed information on claims from US patents and applications[3].

Correcting Inventorship

Legal Framework

The correction of inventorship is governed by 35 U.S.C. § 256, which allows for the correction of errors in naming the inventors of a patent. This process involves filing a petition with the USPTO, including a statement of facts, an oath or declaration by the actual inventors, the required fee, and the written consent of any assignee[1].

Case Law: Stark v. Advanced Magnetics, Inc.

The case of Stark v. Advanced Magnetics, Inc. highlights the complexities involved in correcting inventorship. Dr. Stark's claim to be a joint inventor was dismissed due to a perceived lack of diligence in correcting the inventorship. However, the court ultimately vacated the summary judgment, emphasizing that each patent is a separate entity and that the diligence requirement does not bar correction of inventorship for subsequent patents[1][4].

Patent Landscape and Administrative Challenges

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, significantly altered the U.S. patent landscape by introducing new administrative procedures such as inter partes review (IPR) and post-grant review (PGR). These procedures, managed by the Patent Trial and Appeal Board (PTAB), provide a faster and more cost-effective way to challenge the validity of issued patents compared to federal court litigation[2].

Inter Partes Review (IPR) and Post-Grant Review (PGR)

IPR and PGR allow any person to challenge the validity of a patent before the PTAB, without the need for standing. These processes are generally faster and less expensive than judicial proceedings, requiring a lower standard of proof to invalidate patents. This has made PTAB procedures a preferred route for entities accused of patent infringement[2].

Controversies and Criticisms

Criticisms of PTAB

Despite the efficiency of PTAB procedures, there are criticisms that PTAB is biased against patent holders, creating uncertainty in patent rights and discouraging innovation. Critics argue that IPR, in particular, is unfair to patent holders and can lead to the invalidation of patents that would have been upheld in federal court[2].

State Law Counts and Tort Claims

State Law Implications

In addition to federal patent law, state law can play a significant role in patent disputes. State law counts, including tort claims and contract disputes, can be relevant in cases where patent issues intersect with other legal areas. However, these claims are often subject to different statutes of limitations and may be dismissed if they are time-barred[1].

Key Considerations for Business Professionals

Efficiency and Cost

When dealing with patent disputes, business professionals must consider the efficiency and cost of different legal avenues. PTAB procedures, while faster and cheaper, may not offer the same level of judicial scrutiny as federal court litigation[2].

Diligence in Correcting Inventorship

The case of Stark v. Advanced Magnetics, Inc. underscores the importance of diligence in correcting inventorship. However, the court's ruling emphasizes that each patent should be treated separately, and lack of diligence in one patent does not necessarily bar correction in others[1].

Patent Quality and Scope

Ensuring the quality and scope of patent claims is crucial for maintaining patent validity. This involves careful drafting and analysis of claims to avoid potential challenges and ensure that the invention is adequately protected[3].

Illustrative Statistics

  • The average legal costs for litigating a patent case in federal court exceed $1 million, while PTAB procedures typically cost in the hundreds of thousands of dollars[2].
  • PTAB procedures are designed to reach a final determination within one year of instituting the proceeding, significantly faster than federal court litigation[2].

Quotes from Industry Experts

  • "The creation of PTAB and the introduction of IPR and PGR have significantly altered the landscape of patent litigation, providing a more efficient and cost-effective means to challenge patent validity," - Congressional Research Service[2].

Key Takeaways

  • Patent Claims: The scope and claims of a patent define its legal boundaries and are crucial for determining validity and enforceability.
  • Correcting Inventorship: Errors in inventorship can be corrected under 35 U.S.C. § 256, but require diligence and compliance with specific requirements.
  • PTAB Procedures: IPR and PGR offer faster and more cost-effective alternatives to federal court litigation for challenging patent validity.
  • State Law Implications: State law counts can be relevant in patent disputes but are subject to different legal standards and statutes of limitations.
  • Efficiency and Cost: Business professionals must weigh the efficiency and cost of different legal avenues when dealing with patent disputes.

FAQs

What is the process for correcting inventorship in a patent?

The process involves filing a petition with the USPTO, including a statement of facts, an oath or declaration by the actual inventors, the required fee, and the written consent of any assignee[1].

How do IPR and PGR differ from federal court litigation?

IPR and PGR are faster and less expensive, requiring a lower standard of proof to invalidate patents. They also do not require standing, making them more accessible to entities challenging patent validity[2].

Why is the diligence requirement important in correcting inventorship?

The diligence requirement ensures that inventors take timely action to correct errors in inventorship. However, the court has ruled that each patent should be treated separately in this regard[1].

What are the advantages of using PTAB procedures over federal court litigation?

PTAB procedures are faster, cheaper, and use a lower standard of proof, making them more advantageous for entities challenging patent validity[2].

How do state law counts intersect with patent disputes?

State law counts, including tort claims and contract disputes, can be relevant but are subject to different legal standards and statutes of limitations[1].

Sources

  1. 29 F.3d 1570: Federal court case involving Dr. Stark and Advanced Magnetics, Inc.
  2. Congressional Research Service: Report on the Patent Trial and Appeal Board and Inter Partes Review.
  3. USPTO: Patent Claims Research Dataset documentation.
  4. Case Law: Stark v. Advanced Magnetics, Inc. - Federal Cases - Case Law.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,951,675

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.